Monkeypox concept stock Emergent receives $400 million vaccine order, surges more than 8% in early trading
I'm PortAI, I can summarize articles.
Emergent BioSolutions has received orders for approximately $400 million worth of smallpox, anthrax, and monkeypox vaccines, expected to be delivered in 2024 and 2025. The stock surged more than 16% in pre-market trading and over 8% at the opening. As of now, the company has delivered nearly $210 million in customer orders and has committed to delivering over $185 million in related orders by 2025. The CEO stated that Emergent continues to lead in addressing serious viral threats
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments